![How to make Developer Friends When You Don't Live in Silicon Valley, with Iraqi Engineer Code;Life [Podcast #172]](https://cdn.hashnode.com/res/hashnode/image/upload/v1747360508340/f07040cd-3eeb-443c-b4fb-370f6a4a14da.png?#)
![[Virtual Event] Strategic Security for the Modern Enterprise](https://eu-images.contentstack.com/v3/assets/blt6d90778a997de1cd/blt55e4e7e277520090/653a745a0e92cc040a3e9d7e/Dark_Reading_Logo_VirtualEvent_4C.png?width=1280&auto=webp&quality=80&disable=upscale#){kind=logo}
Pathos AI, which uses AI to develop oncology drugs, raised a $365M Series D at a $1.6B valuation, bringing its total funding to $467M, per PitchBook (Katherine Davis/Axios)
Katherine Davis / Axios: Pathos AI, which uses AI to develop oncology drugs, raised a $365M Series D at a $1.6B valuation, bringing its total funding to $467M, per PitchBook — Pathos AI, a New York drug development startup, raised $365 million in a Series D at a $1.6 billion valuation.
Katherine Davis / Axios:
Pathos AI, which uses AI to develop oncology drugs, raised a $365M Series D at a $1.6B valuation, bringing its total funding to $467M, per PitchBook — Pathos AI, a New York drug development startup, raised $365 million in a Series D at a $1.6 billion valuation.
